Short Interest in Advaxis, Inc. (OTCMKTS:ADXS) Declines By 19.0%

Advaxis, Inc. (OTCMKTS:ADXSGet Rating) saw a significant decline in short interest during the month of April. As of April 30th, there was short interest totalling 663,900 shares, a decline of 19.0% from the April 15th total of 820,100 shares. Based on an average daily volume of 904,800 shares, the short-interest ratio is currently 0.7 days.

A number of large investors have recently added to or reduced their stakes in ADXS. Morgan Stanley lifted its stake in Advaxis by 292.0% in the first quarter. Morgan Stanley now owns 47,207 shares of the biotechnology company’s stock worth $34,000 after acquiring an additional 35,164 shares during the period. Advisor Group Holdings Inc. lifted its stake in Advaxis by 4,394.3% in the third quarter. Advisor Group Holdings Inc. now owns 79,954 shares of the biotechnology company’s stock worth $42,000 after acquiring an additional 78,175 shares during the period. Geode Capital Management LLC lifted its position in shares of Advaxis by 10.5% during the third quarter. Geode Capital Management LLC now owns 1,135,533 shares of the biotechnology company’s stock valued at $592,000 after buying an additional 108,116 shares during the last quarter. GSA Capital Partners LLP purchased a new stake in shares of Advaxis during the third quarter valued at about $80,000. Finally, Millennium Management LLC purchased a new stake in shares of Advaxis during the third quarter valued at about $128,000. 6.72% of the stock is owned by institutional investors.

Separately, StockNews.com assumed coverage on shares of Advaxis in a research report on Tuesday, May 10th. They issued a “sell” rating on the stock.

OTCMKTS ADXS opened at $0.07 on Tuesday. The company’s 50-day moving average price is $0.08 and its 200-day moving average price is $0.13. The stock has a market cap of $9.61 million, a PE ratio of -0.66 and a beta of 2.07. Advaxis has a 12 month low of $0.06 and a 12 month high of $0.76.

Advaxis (OTCMKTS:ADXSGet Rating) last posted its quarterly earnings results on Thursday, March 17th. The biotechnology company reported ($0.03) EPS for the quarter.

Advaxis Company Profile (Get Rating)

Advaxis, Inc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer.

Recommended Stories

Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.